Gilead Sciences

News

Ibrance cleared in US for 'double-positive' breast cancer

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

News

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

FDA starts kicks off review of Gilead's weekly HIV pill

The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.

News

WHO names three 'priority' Ebola drugs for trials

The WHO has named drugs from Regeneron, Mapp Bio, and Gilead that should be fast-tracked through trials to respond to the current Ebola outbreak.

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Gilead claims first FDA nod for a hepatitis D therapy

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

Ibrance cleared in US for 'double-positive' breast cancer

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

FDA starts kicks off review of Gilead's weekly HIV pill

WHO names three 'priority' Ebola drugs for trials

Datroway is first TROP2 drug for frontline breast cancer

Gilead claims first FDA nod for a hepatitis D therapy

UK partners with Eli Lilly on obesity plan

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks